Crazy Volume Spikes for: Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

46

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Belonging to the Medical sector which declined -2% and closed its last trading session at $24.55.

The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 10/17/2016. Currently, the stock has a 1 Year Price Target of $43.63.

The consensus recommendation, according to Zacks Investment research, is 2.63. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.61 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.87 and 2.87 respectively.

Valeant Pharmaceuticals International, Inc. on 6/30/2016 reported its EPS as $1.4. The company beat the analyst EPS Estimate with the difference of $-0.07. This shows a surprise factor of -4.8%.

Many analysts have provided their estimated foresights on Valeant Pharmaceuticals International, Inc. Earnings, with 17 analysts believing the company would generate an Average Estimate of $1.78. Whereas they predicted High and Low Earnings Estimate as $1.95 and $1.65 respectively. While in the same Quarter Previous year, the Actual EPS was $2.74.

Analysts are also projecting an Average Revenue Estimate for Valeant Pharmaceuticals International, Inc. as $2.5 Billion in the Current Quarter. This estimate is provided by 12 analysts. The High Revenue estimate is predicted as 2.55 Billion, while the Low Revenue Estimate prediction stands at 2.42 Billion. The company’s last year sales total was 2.79 Billion.

The Company got Upgrade by Morgan Stanley on 17-Aug-16 from Equal-Weight to Overweight.

Over the period of 6 months, Insider Purchases show a total of 6 transaction in which 30775 shares were traded. 3 Insider Sales transactions were made totaling 4328940 shares traded.

19 analysts projected Price Targets for Valeant Pharmaceuticals International, Inc. The analysts believe that the company stock price could grow as high as $175. The Low Price target projection by analysts is $16 and the Mean Price Target is $43.63.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has the market capitalization of $8.56 Billion. The company rocked its 52-Week High of $179.83 on Oct 16, 2015 and touched its 52-Week Low of $18.55 on Jun 27, 2016. The stock has Return on Assets (ROA) of -2 percent. Return on Equity (ROE) stands at -17% and Return on Investment (ROI) of 3.7 percent.

The stock is currently showing YTD performance of -75.85 Percent. The company has Beta Value of -0.13 and ATR value of 1.14. The Weekly and Monthly Volatility stands at 4.46% and 3.80%.

Company profile:

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.